YAMA'S LEA'S SHIELD FEMALE BARRIER CONTRACEPTIVE NEEDS 200-PATIENT STUDY, FDA PANEL FINDS; EXISTING DATA INSUFFICIENT TO ESTABLISH PREGNANCY RATE
This article was originally published in The Gray Sheet
Executive Summary
Yama's Lea's Shield silicone vaginal barrier contraceptive device should be evaluated in a study of at least 200 subjects, FDA's Obstetrics and Gynecology Devices Panel concluded at its Oct. 21 meeting in Rockville, Maryland.
You may also be interested in...
Yama Lea’s Shield Contraceptive Market Strategy To Focus On Convenience
Yama, Inc. is positioning its Lea's Shield reusable barrier contraceptive device as "more convenient" than traditional diaphragms
Yama Lea’s Shield Contraceptive Market Strategy To Focus On Convenience
Yama, Inc. is positioning its Lea's Shield reusable barrier contraceptive device as "more convenient" than traditional diaphragms
Barrier Contraceptive Devices Three-Month Data OK For Approval, Panel Says
Three-month data is sufficient in demonstrating the efficacy of female barrier contraceptives in preventing pregnancy, a majority of FDA's Obstetrics and Gynecology Devices Panel agreed Oct. 4.